Pharmacogenomics of Antiplatelet Response

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial will examine with effect of 2-week aspirin therapy on platelet gene expression in persons at high-risk of developing heart attacks due to family history of early-onset coronary artery disease

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• 45-75 years

• GeneSTAR participant

• No personal History of Coronary Artery Disease

• Women who are post-menopausal

• Women who are using a reliable method of contraception, such as history of tubal ligation, IUD or taking OCP

Exclusion Criteria:

• Taking aspirin prescribed by physician

• weight < 60 kg

• History of recent or current bleeding

• allergy to aspirin or history of adverse events to aspirin

• serious comorbid conditions (such as AIDS, active cancer)

• high blood pressure (>160/95)

• History of gastrointestinal ulcer/bleeding

• Mental incompetence to make decision to participate.